Published: 2024-04-25
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2024.
THE GROWTH JOURNEY CONTINUES
JANUARY – MARCH 2024
- Net sales increased by 54 percent (54 percent at constant exchange rates) and amounted to SEK 184.4 million (119.7).
- The North America (NA) segment reported a sales growth of 65 percent (65 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 27 percent (24 percent at constant exchange rates).
- The gross margin amounted to 92.6 percent (90.5).
- The operating result before effects from the Group’s incentive programs amounted to SEK 41.6 million (4.6). Reported operating result amounted to SEK 32.3 million (0.8).
- Earnings per share before and after dilution were SEK 0.33 (0.00).
"Successful regulatory milestones and continued strong growth." Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
- In March, the FDA announced that CERAMENT BONE VOID FILLER has been approved for use in Spine Inter Body Fusion (IBF) in the US.
- In March, the FDA announced that CERAMENT G was approved for use in open fractures in the US.
EVENTS AFTER THE REPORTING PERIOD
- Nothing to report.